Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Interferon alpha/beta

3

VI.b Pulmonary arterial hypertension

3
Last update : 21/01/2017
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Pegylated interferon
3

Publications

Pulmonary arterial hypertension associated with interferon-beta treatment for multiple sclerosis. Case report and literature review.
Multiple sclerosis and related disorders 2019 Feb;28;273-275 2019 Feb
Pulmonary arterial hypertension associated with interferon therapy: a population-based study.
Multidisciplinary respiratory medicine 2017;12;1 2017
Interferon-induced pulmonary hypertension: an update.
Current opinion in pulmonary medicine 2016 Sep;22;415-20 2016 Sep
Interferon beta-1a long-term therapy related to pulmonary arterial hypertension in multiple sclerosis patients.
Multiple sclerosis (Houndmills, Basingstoke, England) 2016 Oct;22;1495-1498 2016 Oct
Pulmonary arterial hypertension in patients treated with interferon.
The European respiratory journal 2014 Dec;44;1627-34 2014 Dec
Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C.
Digestive diseases and sciences 2010 Jun;55;1785-90 2010 Jun
Pulmonary artery hypertension during interferon-alpha therapy for chronic myelogenous leukemia.
Annals of hematology 2001 May;80;308-10 2001 May

Powered by

  • ^
  • Contact
  • Cookies
  • About